Balog A et al. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. (2002) IMMUNOLOGY LETTERS 0165-2478 1879-0542 84 3 199-203,
1158109
Szakcikk (Folyóiratcikk) | Tudományos[1158109]
Dutta Sourabh et al. Cerebrospinal fluid and plasma procalcitonin for the diagnosis of neonatal bacterial meningitis. (2022) JOURNAL OF PAEDIATRICS AND CHILD HEALTH 1034-4810 1440-1754
Xu Hua-Guo et al. Clinical utility of procalcitonin and its association with pathogenic microorganisms. (2021) CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES 1040-8363 1549-781X
Niu M.M. et al. Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness. (2021) CLINICAL AND EXPERIMENTAL MEDICINE 1591-8890 1591-9528
Hincu Maura-Adelina et al. Relevance of Biomarkers Currently in Use or Research for Practical Diagnosis Approach of Neonatal Early-Onset Sepsis. (2020) CHILDREN-BASEL 2227-9067 7 12
Zubareva Nadezhda Anatol et al. Association between Abscess Fluid and Procalcitonin in Blood Serum. (2020) JOURNAL OF EXPERIMENTAL AND CLINICAL SURGERY 2070-478X 13 2 109-115
Eschborn Samantha et al. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. (2019) JOURNAL OF PERINATOLOGY 0743-8346 39 7 893-903
Mangogna A. et al. Overview of procalcitonin in pregnancy and in pre-eclampsia. (2019) CLINICAL AND EXPERIMENTAL IMMUNOLOGY 0009-9104 1365-2249 198 1 37-46
Agostinis Chiara et al. Pre-eclampsia affects procalcitonin production in placental tissue. (2018) AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY 1046-7408 1600-0897 79 4
Choi Justin J. et al. Novel applications for serum procalcitonin testing in clinical practice. (2018) EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 1473-7159 1744-8352 18 1 27-34
EL-GAREM N et al. Procalcitonin as a Marker of Infection in Patients with Liver Cirrhosis Compared to C-Reactive Protein. (2016) THE MEDICAL JOURNAL OF CAIRO UNIVERSITY 0045-3803 84 2 163-167
Kiszewska N et al. Selected inflammatory markers in the diagnosis and monitoring of infections in children treated for hematological malignancies. (2015) BIOMARKERS IN MEDICINE 1752-0363 1752-0371 9 5 461-471
Hendek MK et al. Evaluation of salivary procalcitonin levels in different periodontal diseases. (2015) JOURNAL OF PERIODONTOLOGY 0022-3492 86 6 820-826
Rami D et al. The first trimester gravid serum regulates procalcitonin expression in human macrophages skewing their phenotype in vitro. (2014) MEDIATORS OF INFLAMMATION 0962-9351 1466-1861 2014
Tamura M et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP). (2014) JOURNAL OF INFECTION AND CHEMOTHERAPY 1341-321X 1437-7780 20 2 97-103
Wang C et al. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. (2014) EXPERIMENTAL AND THERAPEUTIC MEDICINE 1792-0981 1792-1015 8 4 1075-1080
Mallamaci F et al. Procalcitonin and the inflammatory response to salt in essential hypertension: A randomized cross-over clinical trial. (2013) JOURNAL OF HYPERTENSION 0263-6352 1473-5598 31 7 1424-1430
Skirecki T et al. Sepsis immunopathology: Perspectives of monitoring and modulation of the immune disturbances. (2012) ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS 0004-069X 1661-4917 60 2 123-135
La Camera G et al. Prognostic role of procalcitonin in the early detection of patients at risk of post-operative infection. (2012) ACTA MEDICA MEDITERRANEA 0393-6384 2283-9720 28 2 95-98
Ogasawara T et al. Intrathoracic administration of OK-432 elevates the serum procalcitonin levels. (2012) INTERNAL MEDICINE 0918-2918 1349-7235 51 19 2727-2731
Matwiyoff GN et al. Immune regulation of procalcitonin: Abiomarker and mediator of infection. (2012) INFLAMMATION RESEARCH 1023-3830 1420-908X 61 5 401-409
Wei J X et al. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. (2008) BRITISH JOURNAL OF ANAESTHESIA 0007-0912 1471-6771 100 5 612-621
Krämer P M et al. Development and characterization of new rat monoclonal antibodies for procalcitonin. (2008) ANALYTICAL AND BIOANALYTICAL CHEMISTRY 1618-2642 1618-2650 392 4 727-736
Decaluwe H et al. Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. (2006) PEDIATRIC RESEARCH 0031-3998 1530-0447 59 4 PART 1 579-583
Guz G et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. (2006) PERITONEAL DIALYSIS INTERNATIONAL 0896-8608 1718-4304 26 2 240-248
Bucova M et al. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. (2006) CENTRAL-EUROPEAN JOURNAL OF IMMUNOLOGY 1426-3912 1644-4124 31 3-4 87-93
Bota D P et al. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. (2005) JOURNAL OF LABORATORY AND CLINICAL MEDICINE 0022-2143 1532-6543 1931-5244 146 6 347-351
Herget-Rosenthal S et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. (2005) SCANDINAVIAN JOURNAL OF IMMUNOLOGY 0300-9475 1365-3083 61 2 180-186
Pinčíková T et al. Influence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood against bacteria Staphylococcus aureus and Escherichia coli: Vplyv rekombinantného l'udského prokalcitonínu na fagocytovú a kandidacídnu schopnost' polymorfonukleárnych leukocytov a na cídne mechanizmy séra a krvi voči baktériám Staphylococcus areus a Escherichia coli. (2005) VNITRNI LEKARSTVI 0042-773X 1801-7592 51 12 1365-1370
Hoffmann G. The role of procalcitonin in sepsis and septic shock. (2004) CURRENT MEDICINAL CHEMISTRY: IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS 1568-0134 4 2 143-147
Rau B et al. Procalcitonin: Improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. (2004) LANGENBECKS ARCHIVES OF SURGERY 1435-2443 1435-2451 389 2 134-144
Linscheid P et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. (2004) CRITICAL CARE MEDICINE 0090-3493 1530-0293 32 8 1715-1721
Balog A et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. (2004) PATHOBIOLOGY 1015-2008 1423-0291 71 5 274-280,
1158126
Szakcikk (Folyóiratcikk) | Tudományos[1158126]
Mohammed Samer et al. Association of tumor necrosis factor-alpha promoter region gene polymorphism at positions-308G/A,-857C/T, and-863C/A with etanercept response in Iraqi rheumatoid arthritis Patients. (2022) ARCHIVES OF RHEUMATOLOGY 2148-5046 2618-6500
Salvador-Martin Sara et al. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. (2020) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 21 9
Davignon Jean-Luc et al. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review. (2018) ARTHRITIS RESEARCH & THERAPY 1478-6354 1478-6362 20
Kotovskaya M. A. et al. Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis. (2017) SOVREMENNAYA REVMATOLOGIYA / MODERN RHEUMATOLOGY JOURNAL 1996-7012 2310-158X 11 2 4-17
Dhawan D.. Biotechnology for biomarkers: Towards prediction, screening, diagnosis, prognosis, and therapy. (2017) Megjelent: Omics Technologies and Bio-engineering: Towards Improving Quality of Life pp. 533-557
Oliver J et al. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. (2015) BIOMARKERS IN MEDICINE 1752-0363 1752-0371 9 6 499-512
Song GG et al. Association between TNF-α promoter -308 A/G polymorphism and rheumatoid arthritis: A meta-analysis. (2014) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 34 4 465-471
Umićević Mirkov M et al. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: Towards personalized medicine. (2013) PHARMACOGENOMICS 1462-2416 1744-8042 14 4 425-444
Scardapane A et al. TNF-α polymorphisms in juvenile idiopathic arthritis: Which potential clinical implications?. (2012) INTERNATIONAL JOURNAL OF RHEUMATOLOGY 1687-9260 1687-9279 2012
Tong Q et al. TNF-alpha-857 and-1031 polymorphisms predict good therapeutic response to TNF-alpha blockers in Chinese Han patients with ankylosing spondylitis. (2012) PHARMACOGENOMICS 1462-2416 1744-8042 13 13 1459-1467
McGeough CM et al. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-a therapy.. (2012) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 32 6 1647-1653
McGeough Cathy M. Diagnostic, Prognostic and Theranostic Biomarkers for Rheumatoid Arthritis. (2012) JOURNAL OF CLINICAL AND CELLULAR IMMUNOLOGY 2155-9899 1 S6 1-5
Emonts M et al. Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study. (2011) BMC MEDICAL GENETICS 1471-2350 1471-2350 12
Ingegnoli F et al. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. (2011) AUTOIMMUNITY REVIEWS 1568-9972 1873-0183 10 8 460-463
Papamichaela K et al. Association of TNF and FcγRIIA gene polymorphisms with differential response to infliximab in a Greek cohort of crohn's disease patients. (2011) ANNALS OF GASTROENTEROLOGY 1108-7471 1792-7463 24 1 35-40
Pavy S et al. Tumour necrosis factor α-308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: Systematic review and meta-analysis. (2010) ANNALS OF THE RHEUMATIC DISEASES 0003-4967 1468-2060 69 6 1022-1028
Marotte H et al. Predictive biomarkers of anti-TNF alpha response in rheumatoid arthritis: Biomarqueurs prédictifs de la réponse aux anti-TNF alpha dans la polyarthrite rhumatoïde. (2010) REVUE DU RHUMATISME (EDITION FRANCAISE) 1169-8330 77 5 448-457
O Rielly D et al. TNF-α - 308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: A systematic review and meta-analysis. (2009) PHARMACOGENOMICS JOURNAL 1470-269X 1473-1150 9 3 161-167
Tingting Z et al. Progress of tumor necrosis factor-α antagonist treatment of rheumatoid arthritis drugs genomics research (肿瘤坏死因子-α拮抗剂治疗类风湿关节炎的药物基因组学研究进展). (2009) ZHONGHUA FENGSHIBINGXUE ZAZHI / CHINESE JOURNAL OF RHEUMATOLOGY 1007-7480 12 4 856-859
Tan R et al. Genetic predictors of response to anti-tumor necrosis factor drugs in rheumatoid arthritis.. (2009) Rheumatology Reports 2036-7511 1 e1-e4
Potter C et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. (2009) ANNALS OF THE RHEUMATIC DISEASES 0003-4967 1468-2060 68 1 69-74
Phillips A M et al. Pharmacogenetics and inflammatory bowel disease. (2008) CURRENT PHARMACOGENOMICS & PERSONALIZED MEDICINE 1875-6921 1875-6913 6 3 201-224
Coury F et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy. (2008) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 1593-098X 26 2 234-239
Liu CY et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. (2008) MOLECULAR MEDICINE 1076-1551 1528-3658 14 9-10 575-581
Ongaro A et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFÎą therapy in rheumatoid arthritis?. (2008) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 28 9 901-908
Schmeling H et al. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. (2007) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 27 4 383-386
Rezaieyazdi Z et al. Tumour necrosis factor a -308 promoter polymorphism in patients with rheumatoid arthritis. (2007) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 28 2 189-191
Lee Y H et al. Tumor necrosis factor-Îą promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: A metaanalysis. (2007) JOURNAL OF RHEUMATOLOGY 0315-162X 1499-2752 34 1 43-49
CHEN HB et al. The study of the relation between triptolide inhibits peripheral blood mononuclear cell to secret TNF α and tumour necrosis factor α gene polymorphism. (2007) ZHONGGUO MIANYIXUE ZAZHI / CHINESE JOURNAL OF IMMUNOLOGY 1000-484X 2007 1 49-52
Coenen M J et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. (2007) PHARMACOGENOMICS 1462-2416 1744-8042 8 7 761-773
Guis S et al. Influence of -308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis. (2007) ARTHRITIS & RHEUMATISM (ARTHRITIS CARE & RESEARCH) (2001-2009) 0004-3591 1529-0131 57 8 1426-1430
Castro-Santos P et al. TNFÎą genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type. (2006) CLINICAL IMMUNOLOGY 1521-6616 1521-7035 121 3 305-313
Shenghao TU et al. Relationship between Single Nucleotide Polymorphism in TNF- Gene Promoter Region and Inhibitory Effects of Triptolide on TNFProduction in Peripheral Blood Mononuclear Cells of Healthy Humans.. (2006) Journal of Huazhong University of Science and Technology [Med Sci] 26 3 347-349
Taniguchi A et al. Pharmacogenomics in the treatment of rheumatoid arthritis: Clinical implication and perspective. (2006) PERSONALIZED MEDICINE 1741-0541 1744-828X 3 2 151-163
Cronstein B N. Pharmacogenetics in the rheumatic diseases. (2006) BULLETIN OF THE NYU HOSPITAL FOR JOINT DISEASES 1936-9719 1936-9727 0018-5647 2328-4633 2328-5273 64 1-2 16-19
Lee Y H et al. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-Îą-blockers in rheumatoid arthritis: A meta-analysis. (2006) RHEUMATOLOGY INTERNATIONAL 0172-8172 1437-160X 27 2 157-161
de Vries N et al. The response to anti-TNF-Îą treatment: Gene regulation at the bedside. (2005) RHEUMATOLOGY (UNITED KINGDOM) 1462-0324 1462-0332 44 6 705-707
Mugnier B et al. Reply to the letter by T. Lequerree al. about the editorial entitled "Factors predicting responsiveness to anti-TNF alpha therapy in patients with rheumatoid arthritis: using biotherapies rationally". (2005) JOINT BONE SPINE 1297-319X 1778-7254 72 4 347-348
Balog A et al. Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. (2004) ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA 1217-8950 1588-2640 51 3 263-269,
1359977
Szakcikk (Folyóiratcikk) | Tudományos[1359977]
Lim Sung Ho et al. Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. (2022) JOURNAL OF PERSONALIZED MEDICINE 2075-4426 12 8 p. 1265
Aravilli R. Kowshik et al. The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis. (2021) CURRENT PHARMACEUTICAL BIOTECHNOLOGY 1389-2010 1873-4316 22 8 1014-1029
Zaghlol H.M. et al. Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity. (2019) CENTRAL-EUROPEAN JOURNAL OF IMMUNOLOGY 1426-3912 1644-4124 44 3 277-284
Zagloul HM et al. TUMOR NECROSIS FACTOR GENE POLYMORPHISMS AND THEIR ASSOCIATION WITH SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS, DISEASE ACTIVITY AND SEVERITY. (2016) Egyptian Journal of Laboratory Medicine 1110-1873 28 1 59-70
Kempaiah Prakasha et al. Reduced Hsp70 and Glutamine in Pediatric Severe Malaria Anemia: Role of Hemozoin in Suppressing Hsp70 and NF-kappa B Activation. (2016) MOLECULAR MEDICINE 1076-1551 1528-3658 22 570-584
Chen J. et al. Polymorphism of heat shock protein 70-2 and enterocutaneous fistula in Chinese population. (2014) WORLD JOURNAL OF GASTROENTEROLOGY 1007-9327 2219-2840 20 35 12559-12565
Chen J et al. Crohn's disease and polymorphism of heat shock protein gene HSP70-2 in the Chinese population. (2013) JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 0815-9319 1440-1746 28 5 814-818
Zeng Z. et al. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: A meta-analysis. (2013) MODERN RHEUMATOLOGY 1439-7595 1439-7609 23 3 489-495
Fourati H. et al. Non-HLA autoimmunity genetic factors contributing to Autoimmune Polyglandular Syndrome type II in Tunisian patients. (2012) HUMAN IMMUNOLOGY 0198-8859 73 7 740-746
GUO Xin-ling et al. Correlation analysis of gene polymorphisms of TNF-α and its receptors with rheumatoid arthritis susceptibility and related serological markers. (2012) ACADEMIC JOURNAL OF SECOND MILITARY MEDICAL UNIVERSITY 0258-879X 32 2 155-159
Al-Rayes H. et al. TNF-α and TNF-β gene polymorphism in Saudi rheumatoid arthritis patients. (2011) CLINICAL MEDICINE INSIGHTS: ARTHRITIS AND MUSCULOSKELETAL DISORDERS 1179-5441 4 55-63
Anvari M et al. Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ. (2010) ENDOCRINE 1355-008X 1559-0100 0969-711X 37 2 344-348
Lee Y H et al. Associations between tumor necrosis factor-α (TNF-α) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-α blockers in rheumatoid arthritis: A metaanalysis update. (2010) JOURNAL OF RHEUMATOLOGY 0315-162X 1499-2752 37 4 740-746
Li N et al. Association of tumour necrosis factor alpha (TNF-α) polymorphisms with Graves' disease: A meta-analysis. (2008) CLINICAL BIOCHEMISTRY 0009-9120 1873-2933 41 10-11 881-886
